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OBJECTIVE — To synthesize the cost-effectiveness (CE) of interventions to prevent and
control diabetes, its complications, and comorbidities.
RESEARCH DESIGN AND METHODS — We conducted a systematic review of liter-
ature on the CE of diabetes interventions recommended by the American Diabetes Association
(ADA) and published between January 1985 and May 2008. We categorized the strength of
evidence about the CE of an intervention as strong, supportive, or uncertain. CEs were classiﬁed
as cost saving (more health beneﬁt at a lower cost), very cost-effective ($25,000 per life year
gained [LYG] or quality-adjusted life year [QALY]), cost-effective ($25,001 to $50,000 per LYG
or QALY), marginally cost-effective ($50,001 to $100,000 per LYG or QALY), or not cost-
effective ($100,000 per LYG or QALY). The CE classiﬁcation of an intervention was reported
separately by country setting (U.S. or other developed countries) if CE varied by where the
intervention was implemented. Costs were measured in 2007 U.S. dollars.
RESULTS — Fifty-six studies from 20 countries met the inclusion criteria. A large majority of
theADArecommendedinterventionsarecost-effective.Wefoundstrongevidencetoclassifythe
following interventions as cost saving or very cost-effective: (I) Cost saving— 1) ACE inhibitor
(ACEI) therapy for intensive hypertension control compared with standard hypertension con-
trol; 2) ACEI or angiotensin receptor blocker (ARB) therapy to prevent end-stage renal disease
(ESRD)comparedwithnoACEIorARBtreatment;3)earlyirbesartantherapy(atthemicroalbu-
minuria stage) to prevent ESRD compared with later treatment (at the macroalbuminuria stage);
4) comprehensive foot care to prevent ulcers compared with usual care; 5) multi-component
interventionsfordiabeticriskfactorcontrolandearlydetectionofcomplicationscomparedwith
conventional insulin therapy for persons with type 1 diabetes; and 6) multi-component inter-
ventions for diabetic risk factor control and early detection of complications compared with
standardglycemiccontrolforpersonswithtype2diabetes.(II)Verycost-effective—1)intensive
lifestyleinterventionstopreventtype2diabetesamongpersonswithimpairedglucosetolerance
compared with standard lifestyle recommendations; 2) universal opportunistic screening for
undiagnosed type 2 diabetes in African Americans between 45 and 54 years old; 3) intensive
glycemic control as implemented in the UK Prospective Diabetes Study in persons with newly
diagnosed type 2 diabetes compared with conventional glycemic control; 4) statin therapy for
secondary prevention of cardiovascular disease compared with no statin therapy; 5) counseling
and treatment for smoking cessation compared with no counseling and treatment; 6) annual
screening for diabetic retinopathy and ensuing treatment in persons with type 1 diabetes com-
pared with no screening; 7) annual screening for diabetic retinopathy and ensuing treatment in
persons with type 2 diabetes compared with no screening; and 8) immediate vitrectomy to treat
diabetic retinopathy compared with deferred vitrectomy.
CONCLUSIONS — Manyinterventionsintendedtoprevent/controldiabetesarecostsaving
or very cost-effective and supported by strong evidence. Policy makers should consider giving
these interventions a higher priority.
Diabetes Care 33:1872–1894, 2010
T
he cost of diabetes in the U.S. in
2007was$174billion(1).Manyin-
terventions can reduce the burden
of this disease. However, health care re-
sources are limited; thus, interventions
for diabetes prevention/control should be
prioritized. We wanted to compare the
effectiveness and costs of various inter-
ventions to ﬁnd those that were the most
effective for the least expense. Cost-
effective analysis is a useful tool for this
purpose.Suchanalysesconsistofcompil-
ing incremental cost-effectiveness ratios
(ICERs), which are calculated as a ratio of
the difference in costs to the difference in
effectivenessbetweentheinterventionbe-
ing evaluated and the comparison
intervention.
With the same health outcome indi-
cator, ICERs of interventions are compa-
rable. Therefore, these ICERs can make it
easiertodecidehowtoallocateresources.
Although many cost-effectiveness (CE)
analyses of diabetes interventions have
been published, their qualities and con-
clusions vary. A systematic review, which
appraises individual studies and summa-
rizesresults,wouldaidpolicymakersand
clinicians in prioritizing interventions to
prevent or treat diabetes and its
complications.
Few investigators have conducted
systematic reviews of the CE of diabetes
interventions (2–5). The systematic
review presented here, following the
Cochrane Collaboration’s protocol (6),
includes all English language studies
available from 1985 to May 2008. The
interventions included only those recom-
mended by the 2008 American Diabetes
Association (ADA) Standards of Medical
Care in Diabetes (7).
RESEARCH DESIGN AND
METHODS
Study selection and protocols for
review
We searched the Medical Literature Anal-
ysis and Retrieval System Online (MED-
LINE), Excerpta Medica (EMBASE),
Cumulative Index to Nursing and Allied
Health Literature (CINAHL), PsycINFO,
Sociological Abstracts (Soc Abs), Web of
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to identify relevant studies. We created a
search strategy involving medical subject
headings.Thekeywords—andwhateach
indicated—were:
● Indicating diabetes: 26 key words indi-
cating the disease of diabetes, such as
“type 1 diabetes,” “type 2 diabetes,”
“impaired glucose tolerance,” and “in-
sulin resistance”;
● Indicating costs: (“cost or expendi-
ture”)OR(“costsandcostanalysis”)OR
(“health care costs”) OR (“cost of
illness”);
● Indicating effectiveness: (“beneﬁt”) OR
(“life years”) OR (“quality-adjusted life
years”) OR (“disability adjusted life
years”);
● Indicating CE analysis: [(key words for
costs) AND (keywords for effective-
ness)] OR (“cost-beneﬁt analysis”) OR
(“cost-effectiveness analysis”) OR
(“cost-utility analysis”) OR (“economic
evaluation”).
Database searches were based on
matches in all four keyword categories.
Reference lists of all the included articles
were screened for additional citations,
and Diabetes Care was reviewed manu-
ally, issue by issue, as the journal was ex-
pected to be highly relevant.
Criteria for inclusion in the review
were 1) original CE analysis; 2) interven-
tion directed toward patients with type 1,
type 2, or gestational diabetes mellitus
(GDM) and recommended in the 2008
ADA standards for medical care (7); 3)
outcomes were measured as life years
gained (LYGs) or quality-adjusted life
years gained (QALYs); and 4) publication
intheEnglishlanguageoccurredbetween
January 1985 and May 2008 (2). To en-
sure that only studies with acceptable
quality were included, we limited the
analysis to studies considered good or ex-
cellent according to a 13-item quality-
assessment tool based on the British
Medical Journal authors’ guide for eco-
nomic studies (8).
To make ICERs comparable across
thestudies,allcostsareexpressedas2007
U.S. dollars with adjustment from other
currencies, as needed, using the Federal
Reserve Bank’s annual foreign exchange
rates (9) and from other cost years using
the Consumer Price Index (10). If a study
did not mention the year used in cost cal-
culations, we assumed cost was as of one
year before publication. ICERs were ex-
pressedasdollarsperQALYordollarsper
LYG and were rounded to the nearest
hundred dollars per QALY or LYG.
Classiﬁcation of cost-effectiveness of
interventions
Interventionswereclassiﬁedbasedonthe
level of CE by convention as described in
the literature (2,11,12)—cost saving (an
interventiongeneratesabetterhealthout-
come and costs less than the comparison
intervention) or cost neutral (ICER  0);
very cost-effective (0  ICER  $25,000
per QALY or LYG); cost-effective
($25,000  ICER  $50,000 per QALY or
LYG); marginally cost-effective ($50,000 
ICER  $100,000 per QALY or LYG); or
notcost-effective($100,000perQALYor
LYG)—and whether evidence for the inter-
vention’s CE was strong, supportive, or un-
certain as described below.
Thereweretwogradesofevidencein-
cludedinthe“strong”group.Grade1was
deﬁned as 1) CE of the intervention was
evaluated by two or more studies; 2)
study quality was rated good or excellent;
3) effectiveness of interventions based on
well-conducted, randomized clinical
trials with adequate power and gen-
eralizable results or meta-analysis or a
validated simulation model; 4) effec-
tiveness of interventions rated as level A
(clear evidence from well-conducted,
generalizable, randomized controlled tri-
als that were adequately powered; com-
pelling nonexperimental evidence, i.e.,
the all or none rule developed by the
Centre for Evidence-Based Medicine at
the University of Oxford, U.K.) or level
B (supportive evidence from well-
conducted cohort studies or supportive
evidence from a well-conducted case-
controlstudy)accordingtothe2008ADA
standards of medical care (7); and 5) sim-
ilar ICERs reported across the studies.
Grade 2 was deﬁned as the same as Grade
1 except that the CE was based on only
one study and the study was rated as
excellent.
We called the level of evidence “sup-
portive” if only one study, rated lower
than excellent, evaluated the CE of the
intervention or if the effectiveness of the
intervention was supported by either
level C evidence (supportive evidence
from poorly controlled or uncontrolled
studies, or conﬂicting evidence with the
weightofevidencesupportingtherecom-
mendation) or expert consensus (level E)
in ADA recommendations (7). The term
“uncertain” was used to describe inter-
ventions with inconsistent evidence
about CE across studies.
Reporting the results of the
systematic review
We reported the study results in two
ways: 1) summarizing the key features
and results for each included study; and
2) synthesizing the CE of the interven-
tions based on the classiﬁcation criteria
described above. For the summary, we
grouped interventions based on their in-
tended purposes: a) preventing type 2 di-
abetes among high-risk persons; b)
screeningforundiagnosedtype2diabetes
andGDM;c)managementofdiabetesand
risk factors for complications; d) screen-
ing for and early treatment of complica-
tions; and e) treatment of complications
and comorbidities. We considered cases
where the same intervention was applied
to different populations or was compared
with different interventions as different
speciﬁc interventions and reported the
ICERs separately. This was because both
incremental costs and effectiveness of an
intervention,andthustheICERs,variedif
the population and/or comparison group
differed. If the CE of an intervention was
evaluated from different study perspec-
tives, we report the ICERs separately. We
presented the ICERs in subgroups if their
ICERs differed substantially from base-
case analysis, and original studies re-
ported the ICERs this way. If the study
reported the ICERs only for population
subgroups, we provided a range and,
when available, trend of the ICERs. Fi-
nally, if a study used both LYGs and
QALYs as study outcome measures, we
reported the ICER in both costs per LYG
and QALY.
In reporting the synthesized results,
we applied the following rules: 1)W e
usedthemedianICERtorepresenttheCE
of an intervention if the intervention was
evaluated by more than one study. 2)W e
reported the ICERs from the longer ana-
lytical time horizon if the intervention
was evaluated from both short- and long-
term perspectives. This was appropriate
since many of the beneﬁts of most diabe-
tes prevention and control interventions
would come from preventing diabetic
complications,whichoccurlaterinlife.3)
We chose the health care system as our
primarystudyperspectiveforthepurpose
of cross-study and cross-intervention
comparisons. This study perspective in-
cluded all the medical costs incurred no
matter who paid. 4) If the ICERs of an
intervention differed substantially be-
tweentheU.S.andotherdevelopedcoun-
tries (mainly European countries,
Australia, and Canada), we reported the
Li and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 1873summary results separately by labeling
the ICER for the U.S. or for the other
countries. 5) If the trial on which the CE
of an intervention was based was con-
ducted in a mixed population with type 1
or type 2 diabetes, we assumed the CE
was the same for both types of diabetes.
RESULTS— The search yielded 9,461
abstracts. After reviewing the abstracts
and subsequent reference tracking, we
narrowed the focus to 197 possible origi-
nal CE studies. Further review of the full
textresultedin56CEstudiesthatmetour
inclusion criteria. Figure 1 depicts the
data abstraction process.
Table 1 shows the detailed descrip-
tion of the CE studies that we included
according to intervention type (13–70).
We ﬁrst grouped similar interventions to-
gether, then arranged them chronologi-
cally and by the ﬁrst author’s last name.
Some studies that evaluated multiple in-
terventions appear in more than one cat-
egory. The information used to describe
each study included the intervention be-
ing evaluated; comparison intervention,
population, and country setting; data
sources for the effectiveness of the inter-
vention; study methods; quality of the
study; analytical time horizon; discount
rate (a rate that is used to convert future
costs and beneﬁts into their present val-
ues); and ICER.
Thirty-nine of the 56 studies took a
long-termanalyticaltimehorizon,suchas
20–30 years or lifetime. Nearly all of the
studies with the long-term horizon used
simulationmodeling.Onlyonestudywas
conductedinadevelopingcountry(Thai-
land) (57). There were 48 excellent stud-
ies and 8 good studies. Only three studies
took perspectives other than the health
care system.
The interventions evaluated in these
CE studies covered a wide range: lifestyle
and medication therapy to prevent type 2
diabetes among high-risk individuals
(eight studies); screening for undiag-
nosed type 2 diabetes or GDM (three
studies); intensive glycemic control (12
studies);self-monitoringofbloodglucose
(one study); intensive hypertension con-
trol (four studies); statin therapy for cho-
lesterol control (ﬁve studies); smoking
cessation (one study); diabetic health ed-
ucation program (two studies); diabetes
Figure 1—Selection of cost-effectiveness studies for systematic review of interventions to prevent and control diabetes.
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Cost-effectiveness of diabetes interventions
1884 DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 care.diabetesjournals.orgdisease management program (two stud-
ies); screening to prevent diabetic reti-
nopathy (ﬁve studies); optimal foot care
topreventfootulcerandamputation(two
studies); ACE inhibitor (ACEI) or angio-
tensin receptor blocker (ARB) therapy to
prevent diabetic end-stage renal diseases
(ESRD) (15 studies); comprehensive in-
terventions using a combination of sev-
eral of the above secondary prevention
interventions(twostudies);andinterven-
tions treating diabetic retinopathy and
foot ulcers (two studies).
The classiﬁcation of the interventions
based on their level of CE and strength of
evidenceispresentedinTable2.Foreach
intervention, we also described the num-
berofstudiesthatevaluatedtheCEofthis
intervention, its comparison interven-
tion, and the study population in which
the intervention was implemented. We
reported the median and range of the IC-
ERs across the studies.
Twenty-six interventions were classi-
ﬁed as supported by strong evidence con-
cerning their CE (Table 2). Among these,
six interventions were cost saving, eight
were very cost-effective, six were cost-
effective, two were marginally cost-
effective,andfourwerenotcost-effective.
These interventions consisted of primary
prevention, screening for undiagnosed
type 2 diabetes, diabetic risk factor con-
trol, early prevention of diabetes compli-
cations, and treatment of diabetes
complications.
Thesixcost-savinginterventionswith
strong evidence were 1) ACEI therapy for
intensive hypertension control, as in the
UK Prospective Diabetes Study (UKPDS),
in persons with type 2 diabetes compared
with standard hypertension control; 2)
ACEI or ARB therapy to prevent ESRD for
type 2 diabetes compared with no ACEI
or ARB therapy; 3) early irbesartan ther-
apy at the stage of microalbuminuria to
prevent ESRD in people with type 2 dia-
betes compared with treatment at the
stage of macroalbuminuria; 4) compre-
hensive foot care to prevent ulcers in
mixed population with either type 1 or
type2diabetescomparedwithusualcare;
5) multi-component interventions for di-
abetic risk factor control and early detec-
tion of complications compared with
conventional insulin therapy for persons
with type 1 diabetes; and 6) multi-
component interventions for diabetic risk
factor control and early detection of com-
plications compared with standard glyce-
mic control for persons with type 2
diabetes.
Of the eight very cost-effective inter-
ventions with strong evidence, six were
for persons with type 2 diabetes, one for
persons with type 1 diabetes, and one for
a mixed population with type 1 or type 2
diabetes.Interventionsfortype2diabetes
included: 1) primary prevention through
intensivelifestylemodiﬁcation;2)univer-
sal opportunistic screening for un-
diagnosed type 2 diabetes in African
Americans between 45 and 54 years old;
3) intensive glycemic control as imple-
mented in UKPDS; 4) statin therapy for
secondary prevention of cardiovascular
disease; 5) smoking cessation; and 6) an-
nual screening for diabetic retinopathy
andearlytreatmentofit.Theintervention
for type 1 diabetes was annual screening
for diabetic retinopathy and treating the
positivecases.Theinterventionformixed
population of type 1 and type 2 diabetes
was immediate vitrectomy to treat dia-
betic retinopathy compared with deferral
of vitrectomy.
The six cost-effective interventions
with strong evidence were 1) one-time
opportunistic targeted screening for un-
diagnosedtype2diabetesinhypertensive
persons aged 45 years and older com-
pared with no screening; 2) intensive in-
sulin treatment for persons with type 1
diabetescomparedwithconventionalgly-
cemic control; 3) UKPDS-like intensive
glycemic control applied to the U.S.
health care system among adults younger
than age 54 years with type 2 diabetes
compared with conventional glycemic
control;4)intensiveglycemiccontrolbya
Diabetes Prevention Program (DPP) type
of intensive lifestyle intervention in per-
sons with newly diagnosed type 2 diabe-
tes compared with conventional glycemic
control; 5) statin therapy for primary pre-
vention of cardiovascular disease in per-
sons with type 2 diabetes compared with
nostatintherapy;6)multi-componentin-
terventions including insulin therapy,
ACEI therapy, and screening for retinop-
athy in persons with type 1 diabetes com-
pared with intensive insulin therapy.
The two marginally cost-effective in-
terventions with strong evidence were 1)
intensive glycemic control for all U.S. res-
idents with type 2 diabetes diagnosed at
age 25 years and older compared with
usual care; and 2) screening for diabetic
retinopathy every two years compared
with screening every three years in per-
sons with type 2 diabetes.
The four interventions with strong
evidence of not being cost-effective were
1) one-time universal opportunistic
screeningforundiagnosedtype2diabetes
among those aged 45 years and older
compared with no screening; 2) universal
screening for type 2 diabetes compared
with targeted screening; 3) intensive gly-
cemic control in the U.S. setting for pa-
tients diagnosed with diabetes at older
ages (55–94 years of age) compared with
usual care; and 4) annual screening for
retinopathy compared with screening ev-
ery two years. All these studies were for
type 2 diabetes.
There were 18 speciﬁc interventions
for which their CEs were based only on
“supportive” evidence. Among them, 15
were each supported by one CE study, 13
were supported by level C or level E evi-
dence, and ﬁve were supported by level A
or B evidence as deﬁned in the 2008 ADA
standards of medical care in diabetes (7).
For those interventions with level A or B
evidence, the CE of each intervention was
evaluated by one study with a quality of
being “good.”
In terms of the level of the CE, 10 of
the 18 speciﬁc interventions based on
“supportive” evidence were cost-saving,
including 1) screening using the sequen-
tial method (50-g glucose challenge test
followed by 100-g glucose tolerance test
[GTT]) for GDM in 30-year-old pregnant
women between 24–28 weeks’ gestation
comparedwithnoscreening;2)screening
for GDM using the 100-g GTT method
compared with no screening; 3) the se-
quential method compared with 75-g
GTT screening for GDM; 4) 100-g GTT
compared with 75-g GTT screening for
GDM; 5) diabetes self-management edu-
cation for persons with type 1 diabetes
compared with no education; 6) full-
reimbursement policy for ACEI for pa-
tientswithtype1diabetescomparedwith
patients paying out-of-pocket; 7) full-
reimbursement policy for ACEI for pa-
tientswithtype2diabetescomparedwith
patients paying out-of-pocket; 8) screen-
ingusingamobilecameraataremotearea
and processing data in a reading center
compared with a retina specialist’s visit in
a mixed population of type 1 and type 2
diabetes; 9) screening for diabetic ne-
phropathy and ensuing ACEI or ARB
therapy in persons with type 1 diabetes
compared with no screening; and 10) in-
tensiﬁed foot ulcer treatment in a mixed
population with type 1 or type 2 diabetes
compared with standard treatment.
Seven of the 18 speciﬁc interventions
were very cost-effective: 1) primary pre-
vention of type 2 diabetes in women with
GDM history through intensive lifestyle
Li and Associates
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care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 1889interventioncomparedwithusualcare;2)
universalopportunisticscreeningfortype
2 diabetes in African Americans aged
25–44 years compared with no screen-
ing; 3) 100-g GTT compared with the se-
quential screening method for detecting
GDM in 30-year-old pregnant women
between 24–28 weeks’ gestation; 4) dia-
betes self-management education for per-
sons with type 2 diabetes compared with
no education; 5) disease management
programs using specialist nurse–led clin-
ics to treat and control hypertension or
hyperlipidemia in patients with type 2 di-
abetes in a city in England or a culturally
sensitive case–management training pro-
gram to control diabetes and its risk fac-
torsinaLatinopopulationwithbothtype
1 and type 2 diabetes in a U.S. county
compared with usual care only; 6) self-
monitoring of blood glucose (SMBG)
three times per day compared with no
SMBG in type 2 noninsulin users; and 7)
SMBG once per day compared with no
SMBG in type 2 noninsulin users. One of
the 18 speciﬁc interventions was cost-
effective,i.e.,theuseofmetformintopre-
venttype2diabetesinobesepersonswith
impaired glucose tolerance compared
with standard lifestyle intervention. No
interventions in the “supportive” evi-
dence category were “marginally cost-
effective” or “not cost-effective.”
Currentevidenceisuncertainonhow
the CE of screening for undiagnosed type
2 diabetes would change with the age of
thosescreened.Twostudiesevaluatedthe
CE of screening for undiagnosed type 2
diabetes; one study reported that cost-
effectiveness ratios (CERs) increased with
initial screening age (16) while the other
reported that they decreased with screen-
ing age (35).
CONCLUSIONS — Our systematic
review showed that, with few exceptions,
ADA-recommended interventions for
preventing or treating diabetes and its
complicationswerecostsaving,verycost-
effective, or cost-effective (i.e., with an
ICER of less than $50,000 per QALY or
LYG), although the strength of evidence
varied. Generally, interventions that cost
less than $50,000 per QALY are consid-
ered an efﬁcient use of resources and
worth recommending (11). Interventions
with strong evidence for being cost sav-
ing, very cost-effective, or cost-effective
should be considered for implementa-
tion. Interventions with supportive evi-
dence for being cost saving, very cost-
effective, or cost-effective should be
adopted if extra resources are available or
if similar interventions with strong evi-
dence are unavailable or infeasible in a
speciﬁc setting.
The one intervention recommended
bytheADAthatwasshownasnotCEwas
screening for type 2 diabetes of all U.S.
residents aged 45 years and older. When
considering allocating resources efﬁ-
ciently, universal screening for undiag-
nosed diabetes should be undertaken
with great caution. The high CE ratio for
universal screening for undiagnosed type




person compared with no screening.
However the additional costs associated
with screening and early treatments were
relatively large ($564 per person). Al-
though detecting and treating diabetes
earliercanpreventfuturediabetes-related
complications and their associated medi-
cal costs, such savings are relatively small
($57 per person). Combining the health
beneﬁt and costs would yield an ICER of
more than $1 million per QALY (35). An
alternative to broad screening is to focus
on screening persons with additional risk
factors, such as hypertension. Such tar-
geted screening is shown to be cost-
effective when compared with no
screening or universal screening.
Intensive glycemic control for all U.S.
residents with type 2 diabetes diagnosed
atage25yearsandolderismarginallyCE.
However the cost-effectiveness of this in-
tervention varies by age at the time of the
diabetes diagnosis. The intervention is
cost-effective in persons diagnosed at
25–54 years of age. However, intensive
glycemiccontrolforthosediagnosedwith
diabetesat55yearsofageandolderisnot
cost-effective. In fact, this result is consis-
tent with the ADA’s recommendation of
less stringent A1C goals for patients with
limited life expectancies.
The ADA recommended annual eye
screening for diabetic retinopathy. This
recommended intervention is very cost-
effective compared with no screening in
persons with type 2 diabetes. If consider-
ing the efﬁcient allocation of resources,
however, screening every other year
might be a better alternative. Screening
annually leads to a small health beneﬁt
but results in a moderate additional cost.
For example, Vijan et al. (69) showed
that, compared with a 2-year screening,
annual screening among persons at mod-
erate risk (65 years old with A1C level
9%) resulted in an increase of 2–3 days of
sight at a cost of $540–690 per person.
HowevertheADAalsostatedinitsrecom-
mendation that “less frequent exams (ev-
ery 2–3 years) may be considered
following one or more normal eye
exams.”
For the interventions with uncertain
CE (including optimal age of starting
screening for type 2 diabetes), following
the current treatment guidelines may be
the best option until more evidence on
their CE is available.
The CEs of 43 ADA-recommended
interventions were evaluated. Of these,
25wereinthe“strong”evidencecategory.
This number would probably have been
largerifwehadusedlessstringentcriteria
to deﬁne evidence as being strong. For
example, evidence on the CE of using
metformin to prevent type 2 diabetes
among high-risk individuals was consid-
ered “supportive” in our current classiﬁ-
cation even though the efﬁcacy of the
intervention was shown by well-
conducted multi-center large clinical tri-
als in different country settings (71,72),
and its CE was evaluated by “excellent”
CE studies (25,34). This intervention was
considered to have supportive evidence
because it ranked lower in the ADA rec-
ommendations (7).
Among all the interventions consid-
ered, evidence for the CE of primary pre-
vention through intensive lifestyle
modiﬁcation was the strongest regarding
the quantity and quality of the CE studies
and efﬁcacy data. Several well-conducted
clinical trials have shown the efﬁcacy of
intensive lifestyle modiﬁcation in pre-
venting diabetes in different country set-
tings, such as the U.S. DPP (71), Finnish
DiabetesPreventionStudy(73),ChinaDa
QingDiabetesPreventionStudy(74),and
Indian DPP (72). Eight cost-effectiveness
studies (seven of them rated as excellent
quality) have been conducted by different
groups in different countries based on data
from these well-conducted clinical trials
(15,25,34,36,41,50,59,66). The results
fromthesestudiesconsistentlyshowedthat
intensive lifestyle modiﬁcation in persons
with impaired glucose tolerance was cost
savingorverycost-effectiveinthelongrun
(15,25,34,36,41,50,59). Even in a short-
term and one-on-one consulting setting,
the intervention remained cost-effective
(66). The intervention would be more
cost-effectivethanexistingstudiesshowif
the cost of the lifestyle intervention could
be reduced. This might be achieved by
changing the setting in which the inter-
Cost-effectiveness of diabetes interventions
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found a DPP-like intervention to be mar-
ginally cost-effective (25). Even in this
study, however, the intervention would
have been very cost-effective (23) if done
in the type of group environment that is
most likely in a real-world setting. A
group-based, DPP-style lifestyle interven-
tion partnership with the YMCA costs
$275 to $325 per participant in the ﬁrst
year compared with $1,400 in the one-
on-one setting of the DPP trial (75). Pre-
venting diabetes, in particular by lifestyle
modiﬁcation,isnotonlyeffectivebutalso
a very efﬁcient use of health care
resources.
TheCEofaninterventioncanvaryby
country setting. For example, intensive
glycemic control (with a goal A1C level of
7%) in type 2 diabetic patients diagnosed
at 25 years of age and older was margin-
ally cost-effective in the U.S. but very
cost-effective in other developed coun-
tries. Although the efﬁcacy data of all
studies of intensive glycemic control in
type2diabeticpatientswerebasedonthe
same UKPDS data, the cost data were
based on how residents of the different
countries used health services and the
cost of those services. The incremental
cost of intensive glycemic control was
much higher in the U.S. than in the U.K.
because of different practice patterns. Pa-
tients outside the U.S. did not receive di-
abetes disease management services and
had less frequent self-testing and physi-
cian ofﬁce visits than their U.S. counter-
parts at the time these studies were
conducted. If using the health services as
described in the UKPDS setting but with
the U.S. cost of these services, the CE of
the intensive glycemic control in the U.S.
would resemble that of other developed
countries.
Future economic evaluation of diabe-
tes interventions should consider the fol-
lowing. First, more studies are needed to
evaluate the CE of interventions that fell
inthe“supportive”evidencecategory.For
studies with weaker efﬁcacy data, further
efﬁcacy studies are needed. Second, there
are also 38 interventions recommended
by the ADA but they have not been eval-
uated for their CE or the studies did not
meet the inclusion criteria for our review
(list is available upon request from the
authors). The CE of these interventions
should be assessed. Third, more CE stud-
ies are needed that address interventions
in real-world settings. For example, few
studies considered attrition rate, non-
compliance,anddropoutratesinevaluat-
ing CE. Fourth, more studies are needed
to evaluate the CE of public policy
changes.Onlytwostudiesevaluatedpub-
lic insurance reimbursement of ACEI
therapy and both found this intervention
to be cost saving. Finally, the CE of mul-
tiple interventions needs to be evaluated.
In most real-world settings, patients re-
ceive multiple interventions simulta-
neously. Nearly all previous studies only
evaluated the CE of a single intervention.
This review’s conclusions should be
used with caution. First, our conclusions
are based on available information up to
May 2008. More studies have been pub-
lished since then. In addition, data on
both the effectiveness and cost of an in-
tervention could have changed since the
time the original study was conducted.
Using the newly available data could
change our current conclusion. For ex-
ample, in our review, we concluded that
theCEofoptimalagetostartscreeningfor
type 2 diabetes was uncertain. A recently
published CE study on age at initiation of
screening for type 2 diabetes, released af-
ter our analysis was complete, might
change that conclusion (76). Another ex-
ample is the large decrease in costs for
metformin, statins, and ACEIs. Studies
thatevaluateCEusingcurrentcostsmight
look more favorably on interventions that
include statins and ACEIs than those re-
ported here. Reevaluating the costs and
beneﬁts of these interventions, using cur-
rent-day costs, is beyond the scope of this
study.Second,whenusingtheresultsand
conclusionsofourreview,readersneedto
be certain that terms are understood cor-
rectly. For example, “intensive insulin
treatment” in our review meant “multiple
insulin injection” or “insulin infusion.”
Developments in medical technology
might make continuous glucose monitor-
ing systems, which record blood glucose
levelsthroughoutthedayandnight,more
common. Drugs such as TZD Byetta and
Gliptin, not available at the time covered
by this review, are increasingly used to
achieve intensive glycemic control. The
CE of treatment with these and other new
devices and drugs are unknown. New CE
analyses are needed for these new inter-
ventions. Third, not everyone will neces-
sarilyagreewithourclassiﬁcationcriteria.
Differentclassiﬁcationcriteriamighthave
changed some conclusions. Fourth, most
of the CE studies are based on simulation
modeling.Althoughgood-qualitysimula-
tion modeling can provide information at
a much lower cost than clinical trials,
models are based on assumptions and
represent a simpliﬁcation of—and there-
fore might depart from—reality. Fifth,
these CE studies use different methods,
whichcouldaccountforsomedifferences
inCERs.Iftheresultsfromdifferentmod-
els were consistent, we would have more
conﬁdenceintheconclusionontheCEof
the intervention. Sixth, we used the same
threshold for the classiﬁcation of the CE
of interventions regardless of whether the
ICERs were expressed as dollars per LYG
or dollars per QALY, although they are
different measures. The studies that re-
ported costs per LYG did not incorporate
the impact of the intervention on quality
of life into the analysis. If they did, the
cost per QALY could be higher, lower, or
the same depending on the relative mag-
nitude of the health beneﬁt of the inter-
vention on quality of life. Seventh, the
interpretationoftheCEofanintervention
must include consideration of variables
such as study population, comparison in-
terventions, and country setting. Lastly,
our recommendations are based on the
CE of the interventions and not their efﬁ-
cacy; therefore, these recommendations are
notnecessarilythesameastheADArecom-
mendations.
The importance of CE in decision
making should not be overstated. CE is
only one aspect to consider. CE analysis
does not address the distribution of costs
and the beneﬁts of an intervention, soci-
etal or personal willingness to pay, social
and legal aspects, or ethical issues associ-
ated with each intervention. All these as-
pects are important in formulating public
policy. The good news is that our study
shows that a majority of the recom-
mended diabetes interventions provide
both health beneﬁts and good use of
health care resources.
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